Literature DB >> 20516027

The symptom burden index: development and initial findings from use with patients with systemic sclerosis.

Michael A Kallen1, Maureen D Mayes, Yana L Kriseman, Sofia B de Achaval, Vanessa L Cox, Maria E Suarez-Almazor.   

Abstract

OBJECTIVE: Our study had 3 aims: (1) to evaluate the functioning of the Symptom Burden Index (SBI) in patients with systemic sclerosis (SSc); (2) to determine the amount of burden per problem experienced by patients as well as the number of patients experiencing each measured problem area, and the number of SSc problems per patient; and (3) to characterize the burden profiles of problem area-specific subgroups of patients.
METHODS: We developed the SBI to determine the effect of problems in 8 major symptomatic areas of importance to patients (skin, hand mobility, calcinosis, shortness of breath, eating, bowel, sleep, and pain).
RESULTS: Sixty-two patients with SSc completed questionnaires on current disease-related problems, physical functioning, and health status. On average, patients were 53.4 years old and had had SSc for 8 years. Patients were mainly women (87%), English-speaking (87%), with diffuse SSc (63%), white (69%), married (61%), and lived with 1 or more additional household members (84%). Only 26% were employed full-time. The 3 most widely reported problem areas were pain, hand, and skin, experienced by 92%, 89%, and 88%, respectively. About one-third reported experiencing 0-5 problems and one-third 7-8 problems; individual patients experienced, on average, 5.7 problems.
CONCLUSION: Psychometric evaluation determined that (1) summarizing SBI problem area item sets to report burden scores per problem measured is justified; (2) the 8 proposed problem areas are independent and deserve separate evaluation; and (3) burden scores correlate as expected with the Health Assessment Questionnaire-Disability Index and the Medical Outcomes Study Short-Form 36 questionnaire. The number of problems experienced and the degree of problem-associated burden that patients with SSc bear are substantial. Use of the SBI's patient-focused measurements may aid physicians in resolving problems most directly affecting patients' quality of life. This approach to measuring symptomatic burden in patients with chronic disease could be extended to other conditions.

Entities:  

Mesh:

Year:  2010        PMID: 20516027      PMCID: PMC3887547          DOI: 10.3899/jrheum.090504

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  Development of a provisional core set of response measures for clinical trials of systemic sclerosis.

Authors:  D Khanna; D J Lovell; E Giannini; P J Clements; P A Merkel; J R Seibold; M Matucci-Cerinic; C P Denton; M D Mayes; V D Steen; J Varga; D E Furst
Journal:  Ann Rheum Dis       Date:  2007-09-24       Impact factor: 19.103

2.  Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.

Authors:  Dinesh Khanna; Daniel E Furst; Philip J Clements; Grace S Park; Ron D Hays; Jeonglim Yoon; Joseph H Korn; Peter A Merkel; Naomi Rothfield; Fredrick M Wigley; Larry W Moreland; Richard Silver; Virginia D Steen; Michael Weisman; Maureen D Mayes; David H Collier; Thomas A Medsger; James R Seibold
Journal:  J Rheumatol       Date:  2005-05       Impact factor: 4.666

3.  Development and validation of a self-administered systemic sclerosis questionnaire (SySQ).

Authors:  J Ruof; P Brühlmann; B A Michel; G Stucki
Journal:  Rheumatology (Oxford)       Date:  1999-06       Impact factor: 7.580

4.  The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis.

Authors:  J L Poole; V D Steen
Journal:  Arthritis Care Res       Date:  1991-03

Review 5.  The assessment of the patient with systemic sclerosis.

Authors:  Gabriele Valentini
Journal:  Autoimmun Rev       Date:  2003-10       Impact factor: 9.754

6.  A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index.

Authors:  D Khanna
Journal:  Rheumatology (Oxford)       Date:  2008-10       Impact factor: 7.580

Review 7.  Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6.

Authors:  Peter A Merkel; Philip J Clements; John D Reveille; Maria E Suarez-Almazor; Gabriele Valentini; Daniel E Furst
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

Review 8.  Update on indices of disease activity in systemic sclerosis.

Authors:  Marie Hudson; Russell Steele; Murray Baron
Journal:  Semin Arthritis Rheum       Date:  2007-03-23       Impact factor: 5.532

9.  Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms.

Authors:  Elisabetta Danieli; Paolo Airò; Lorenzo Bettoni; Massimo Cinquini; Chiara M Antonioli; Ilaria Cavazzana; Franco Franceschini; Roberto Cattaneo
Journal:  Clin Rheumatol       Date:  2004-08-06       Impact factor: 2.980

10.  Concurrent validity of the Health Assessment Questionnaire Disability Index in Scleroderma.

Authors:  J L Poole; C A Williams; D A Bloch; B Hollak; P Spitz
Journal:  Arthritis Care Res       Date:  1995-09
View more
  7 in total

1.  New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN).

Authors:  Brett D Thombs; Lisa R Jewett; Shervin Assassi; Murray Baron; Susan J Bartlett; Angela Costa Maia; Ghassan El-Baalbaki; Daniel E Furst; Karen Gottesman; Jennifer A Haythornthwaite; Marie Hudson; Ann Impens; Annett Korner; Catarina Leite; Maureen D Mayes; Vanessa L Malcarne; Sarosh J Motivala; Luc Mouthon; Warren R Nielson; Diane Plante; Serge Poiraudeau; Janet L Poole; Janet Pope; Maureen Sauve; Russell J Steele; Maria E Suarez-Almazor; Suzanne Taillefer; Cornelia H van den Ende; Erin Arthurs; Marielle Bassel; Vanessa Delisle; Katherine Milette; Allison Leavens; Ilya Razykov; Dinesh Khanna
Journal:  Clin Exp Rheumatol       Date:  2012-05-29       Impact factor: 4.473

Review 2.  Patient-reported outcome instruments in clinical trials of systemic sclerosis.

Authors:  John D Pauling; Joana Caetano; Corrado Campochiaro; Giacomo De Luca; Ana Maria Gheorghiu; Maria Grazia Lazzaroni; Dinesh Khanna
Journal:  J Scleroderma Relat Disord       Date:  2019-11-25

3.  Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND): Study protocol.

Authors:  Marie-Eve Carrier; Linda Kwakkenbos; Isabelle Boutron; Joep Welling; Maureen Sauve; Cornelia van den Ende; Anne A Schouffoer; Marie Hudson; Brett D Thombs; Luc Mouthon
Journal:  J Scleroderma Relat Disord       Date:  2017-10-16

4.  Use of the Patient-generated Index in systemic sclerosis to assess patient-centered outcomes.

Authors:  Sofia de Achaval; Michael A Kallen; Maureen D Mayes; Maria A Lopez-Olivo; Maria E Suarez-Almazor
Journal:  J Rheumatol       Date:  2013-06-15       Impact factor: 4.666

5.  Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis.

Authors:  Alexandra B Wiese; Veronica J Berrocal; Daniel E Furst; James R Seibold; Peter A Merkel; Maureen D Mayes; Dinesh Khanna
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-11       Impact factor: 4.794

6.  Patient perception of disease burden in diffuse cutaneous systemic sclerosis.

Authors:  Dinesh Khanna; Yannick Allanore; Christopher P Denton; Marco Matucci-Cerinic; Janet Pope; Barbara Hinzmann; Siobhan Davies; Janethe de Oliveira Pena; Oliver Distler
Journal:  J Scleroderma Relat Disord       Date:  2019-08-21

7.  Randomized feasibility trial of the Scleroderma Patient-centered Intervention Network hand exercise program (SPIN-HAND).

Authors:  Linda Kwakkenbos; Marie-Eve Carrier; Joep Welling; Kimberly A Turner; Julie Cumin; Mia Pépin; Cornelia van den Ende; Anne A Schouffoer; Marie Hudson; Ward van Breda; Maureen Sauve; Maureen D Mayes; Vanessa L Malcarne; Warren R Nielson; Christelle Nguyen; Isabelle Boutron; François Rannou; Brett D Thombs; Luc Mouthon
Journal:  PeerJ       Date:  2022-08-04       Impact factor: 3.061

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.